Yahoo · Sep 28, 2026
Is Johnson & Johnson (JNJ) Building a Stronger Post-Stelara Growth Story?
On September 25, Johnson & Johnson (NYSE:JNJ) announced top-line findings from its Phase 4 STAR study evaluating Tremfya (guselkumab) in biologic-naïve adults with active psoriatic arthritis (PsA) and axial involvement. Tremfya met primary and secondary endpoints, demonstrating improvements in axial symptoms alongside MRI-confirmed reductions in joint inflammation. As the first randomized, placebo-controlled study to prospectively […]
